Pharmacokinetics of Antidepressants in Patients with Hepatic Impairment

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Pharmacokinetics

• Publication date

  2014-09-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40262-014-0187-5PMID 25248846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

  2014cited by this paper
• Physicians' Desk Reference

  2014cited by this paper
• A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Depression and Obsessive-Compulsive Disorder

  2012cited by this paper
• A Review of its Pharmacology and Therapeutic Potential in the Management of Panic Disorder

  2012cited by this paper
• Rediscovering Trazodone for the Treatment of Major Depressive Disorder

  2012cited by this paper
• Escitalopram

  2012cited by this paper
• Duloxetine

  2011cited by this paper
• The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment.

  2011cited by this paper
• Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects.

  2011cited by this paper
• Pharmacokinetic Changes of Psychotropic Drugs in Patients with Liver Disease

  2009cited by this paper
• Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report.

  2009cited by this paper
• Enzyme inhibition and induction in liver disease.

  2008cited by this paper
• Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

  2008cited by this paper
• Relevant issues in the monitoring and the toxicology of antidepressants.

  2008cited by this paper
• Pharmacokinetics and dosage adjustment in patients with renal dysfunction

  2008cited by this paper
• Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events.

  2008cited by this paper
• A retrospective pooled analysis of duloxetine safety in 23 983 subjects

  2007cited by this paper
• The Clinical Pharmacokinetics of Escitalopram

  2007cited by this paper
• The pharmacokinetics of escitalopram in patients with hepatic impairment

  2006cited by this paper
• Case report: fulminant hepatic failure involving duloxetine hydrochloride.

  2006cited by this paper
• Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor

  2006cited by this paper
• Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects.

  2005cited by this paper
• Clinical implications of changes in hepatic drug metabolism in older people

  2005cited by this paper
• Pharmacokinetics of paroxetine in patients with cirrhosis

  2004cited by this paper
• A High‐Performance Liquid Chromatography Method with Photodiode‐Array UV Detection for Therapeutic Drug Monitoring of the Nontricyclic Antidepressant Drugs

  2003cited by this paper
• Influence of liver cirrhosis on sertraline pharmacokinetics.

  2003cited by this paper
• Long‐term efficacy and therapeutic drug monitoring of sertraline in major depression

  2003cited by this paper
• Model for end‐stage liver disease and Child‐Turcotte‐Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients

  2002cited by this paper
• Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels.

  2002cited by this paper
• Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.

  2002cited by this paper
• Clinical Pharmacokinetics of Reboxetine, a Selective Norepinephrine Reuptake Inhibitor for the Treatment of Patients with Depression

  2000cited by this paper
• Clinical Pharmacokinetics of Mirtazapine

  2000cited by this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors.

  2000cited by this paper
• Metabolism of Tricyclic Antidepressants

  1999cited by this paper
• Effects of Liver Disease on Pharmacokinetics

  1999cited by this paper
• Long term efficacy of paroxetine in major depression: A study with plasma levels.

  1999cited by this paper
• Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

  1998cited by this paper
• Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects

  1998cited by this paper
• Paroxetine

  1997cited by this paper
• Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.

  1997cited by this paper
• Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

  1997cited by this paper
• The Role of Metabolites of Antidepressants in the Treatment of Depression

  1997cited by this paper
• Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.

  1997cited by this paper
• Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

  1997cited by this paper
• Sertraline

  1997cited by this paper
• Citalopram

  1997cited by this paper
• Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system.

  1996cited by this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance.

  1996cited by this paper
• Pharmacokinetic profile of mirtazapine

  1996cited by this paper
• Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment

  1996cited by this paper
• P-2-18 Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment

  1996cited by this paper
• Antidepressant Drug Interactions and the Cytochrome P450 System

  1995cited by this paper
• N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.

  1995cited by this paper
• Overview of the pharmacokinetics of fluvoxamine.

  1995cited by this paper
• Active Hydroxymetabolites of Antidepressants

  1995cited by this paper
• Clinical Pharmacokinetics of Fluoxetine

  1994cited by this paper
• Pharmacokinetic Optimisation of Therapy with Newer Antidepressants

  1994cited by this paper
• A simplified method to determine galactose elimination capacity in patients with liver disease.

  1993cited by this paper
• Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

  1993cited by this paper
• Pharmacokinetics of trazodone during multiple dosing to psychiatric patients.

  1993cited by this paper
• Pharmacokinetics of Fluvoxamine Maleate in Patients with Liver Cirrhosis after Single-Dose Oral Administration

  1993cited by this paper
• Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects

  1992cited by this paper
• Pharmacokinetics of the selective serotonin reuptake inhibitors.

  1992cited by this paper
• Comparison of SPECT applications in neurology and psychiatry.

  1992cited by this paper
• Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.

  1992cited by this paper
• Clinical Pharmacokinetics of Clomipramine

  1991cited by this paper
• Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine

  1991cited by this paper
• Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease.

  1990cited by this paper
• Clinical overview of serotonin reuptake inhibitors.

  1990cited by this paper
• Clinical Pharmacokinetics of Imipramine and Desipramine

  1990cited by this paper
• Buspirone in clinical practice.

  1990cited by this paper
• Role of Cytochromes P45O in Drug Metabolism and Hepatotoxicity

  1990cited by this paper
• Paroxetine: pharmacokinetic and antidepressant effect in the elderly

  1989cited by this paper
• The pharmacokinetics of paroxetine in the elderly

  1989cited by this paper
• The pharmacokinetics of paroxetine in renal impairment

  1989cited by this paper
• Fluoxetine disposition and elimination in cirrhosis

  1988cited by this paper
• Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly.

  1988cited by this paper
• Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers

  1988cited by this paper
• Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

  1986cited by this paper
• Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach.

  1986cited by this paper
• Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach.

  1986cited by this paper
• Discrepancies Between Pharmacokinetic Studies of Amitriptyline

  1985cited by this paper
• Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants.

  1985cited by this paper
• Altered Amitriptyline Kinetics in a Depressed Patient with Porto-Caval Anastomosis

  1985cited by this paper
• Imipramine and desipramine disposition in the elderly.

  1985cited by this paper
• Plasma levels of amitriptyline: effect of age and sex.

  1985cited by this paper
• Pharmacokinetics of Single Oral Doses of Nortriptyline in Depressed Elderly Hospital Patients and Young Healthy Volunteers

  1980cited by this paper
• PHARMACOKINETICS AND CLINICAL RESPONSE TO TRICYCLIC ANTIDEPRESSANTS

  1980cited by this paper
• Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline.

  1979cited by this paper
• A comparative study of trazodone serum concentrations in patients with normal or impaired renal function.

  1978cited by this paper
• Plasma-nortriptyline levels in endogenous depression.

  1973cited by this paper
• Transection of the oesophagus for bleeding oesophageal varices

  1973cited by this paper
• III. On the structure of the human placenta, and its connexion with the uterus

  1833cited by this paper

• Evaluation and Management of Primary Sclerosing Cholangitis Patients Awaiting Liver Transplantation

  2026cites this paper
• Five-Year Trends in SSRI Consumption: A Precision Medicine Approach to Comparative Analysis Between Serbia and European Countries

  2025cites this paper
• Relationship Between Depression and Chronic Liver Disease: Potential Role of Antidepressants in Modulating Liver Fibrosis.

  2025cites this paper
• Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment

  2025cites this paper
• Paroxetine attenuated liver fibrosis in liver of bile duct ligated rats: role of P2X4 purinoreceptor

  2025cites this paper
• Treatment of Pain in Cirrhosis: Advice to Caregivers of Those with Rock Livers.

  2024cites this paper
• Top Ten Tips Palliative Care Clinicians Should Know About the Physical Manifestations of Psychiatric Illness and Treatment

  2024cites this paper
• Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review

  2023cites this paper
• Individualisation du traitement antidépresseur : suivi thérapeutique pharmacologique et tests pharmacogénétiques

  2023cites this paper
• Antidepressants- and antipsychotics-induced hepatotoxicity

  2021cites this paper
• Pharmacological Interventions in Older Adults

  2019cites this paper
• Depression in the medically ill

  2019cites this paper